Copyright © 1995 by the European Society of Cardiology.
© 1995 The European Society of Cardiology
Collagen turnover and its regulation in the normal and hypertrophying heart
Division of Cardiopulmonary Biochemistry, Department of Medicine, University College London, The Rayne Institute London, U.K.
Jill E. Bishop, PhD, Division of Cardiopulmonary Biochemistry. Department of Medicine, University College London. The Rayne Institute, 5 University Street, London W1CE 6JJ, U.K.
Eighteen different collagen types have now been identified, at least five of which are found in the extracellular matrix of the heart. The interstitial collagens, types I and III are the most abundant components. Due to their tensile strength and arrangement in a network, surrounding and inter-connecting myocytes and capillaries, these collagens transmit forces throughout the myocardium, maintain cardiac structure during the cardiac cycle and contribute to the visco-elastic properties of the myocardium. Early application ofisotopic techniques to assess turnover suggested that heart collagen, in contrast to cyto-plasmic proteins, was virtually inert. The later development of more accurate methods for measuring its synthesis and degradation rates revealed that collagen turnover was quite rapid and that heart cells synthesize and degrade collagens throughout life. Thus, changes in the balance between synthesis and degradation may lead to changes in the composition of the collagen network, which may have marked effects on compliance, resulting in changes in heart function. Current research is focused on the role of mechanical forces and growth factors in the regulation of collagen metabolism. An understanding of the regulatory mechanisms involved in controlling collagen metabolism is fundamental to the development of agents that may reverse or prevent excess collagen deposition in ardiovascular diseases.
Key Words: Collagen metabolism • collagen types • cardiac hypertrophy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. D. Bradshaw, C. F. Baicu, T. J. Rentz, A. O. Van Laer, J. Boggs, J. M. Lacy, and M. R. Zile Pressure Overload-Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic Function: Role of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Post-Synthetic Procollagen Processing Circulation, January 20, 2009; 119(2): 269 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Brower, J. D. Gardner, M. F. Forman, D. B. Murray, T. Voloshenyuk, S. P. Levick, and J. S. Janicki The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur. J. Cardiothorac. Surg., October 1, 2006; 30(4): 604 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Baudino, W. Carver, W. Giles, and T. K. Borg Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1015 - H1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Alla, A. Kearney-Schwartz, A. Radauceanu, S. D. Dores, B. Dousset, and F. Zannad Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes Eur J Heart Fail, March 1, 2006; 8(2): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Camelliti, T. K. Borg, and P. Kohl Structural and functional characterisation of cardiac fibroblasts Cardiovasc Res, January 1, 2005; 65(1): 40 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Asanuma, T. Minamino, S. Sanada, S. Takashima, H. Ogita, A. Ogai, M. Asakura, Y. Liao, Y. Asano, Y. Shintani, et al. {beta}-Adrenoceptor Blocker Carvedilol Provides Cardioprotection via an Adenosine-Dependent Mechanism in Ischemic Canine Hearts Circulation, June 8, 2004; 109(22): 2773 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.L. Komarov, E.P. Panchenko, A.B. Dobrovolsky, Yu.A. Karpov, A.D. Deev, E.V. Titaeva, K.K. Davletov, A.R. Eshkeeva, and L.A. Markova D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease Eur. Heart J., August 2, 2002; 23(16): 1309 - 1316. [Abstract] [PDF]
|
|
|
|
|
|
A. Cargnoni, C. Ceconi, P. Bernocchi, A. Boraso, G. Parrinello, S. Curello, and R. Ferrari Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability Cardiovasc Res, August 18, 2000; 47(3): 556 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takusagawa, S. Komori, K. Matsumura, M. Osada, I. Kohno, K. Umetani, T. Ishihara, T. Sawanobori, H. Ijiri, and K. Tamura The Inhibitory Effects of Carvedilol Against Arrhythmias Induced by Coronary Reperfusion in Anesthetized Rats Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 105 - 112. [Abstract] [PDF]
|
|
|
|
|
|
J. P.M Cleutjens, W.M. Blankesteijn, M. J.A.P Daemen, and J. F.M Smits The infarcted myocardium: Simply dead tissue, or a lively target for therapeutic interventions Cardiovasc Res, November 1, 1999; 44(2): 232 - 241. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1194 - 1200. [Abstract] [Full Text] [PDF]
|
|